Biophytis Announces Three Oral and One Poster Presentations at the 2019 International Conference on Frailty and Sarcopenia Research Feb 18, 2019 01:00AM
BIOPHYTIS Strengthens its Senior Management Team and Continues its Expansion in the United States Dec 17, 2018 01:30AM
BIOPHYTIS Announces One Oral Presentation and Two Poster Presentations at the 11th International Conference on Cachexia, Sarcopenia and Muscle Wasting Dec 7, 2018 01:47PM
BIOPHYTIS to Host Key Opinion Leader Meeting on the Biology of Aging and its Application in Neuromuscular Diseases Nov 27, 2018 12:00PM
BIOPHYTIS : Interim Results 2018 and Perspective on Activity Oct 22, 2018 01:56PM


Sep 13, 2018 12:00PM BIOPHYTIS Obtains a €10 Million Loan With Kreos Capital
Sep 4, 2018 01:30AM BIOPHYTIS Provides Enrollment Update in Its Phase 2b SARA-OBS and SARA-INT Studies of Sarconeos in Sarcopenia
May 24, 2018 12:00PM BIOPHYTIS: Inclusion of the First Patient in Phase 2b Study in Sarcopenia
May 15, 2018 02:22PM BIOPHYTIS Receives Orphan Drug Designation in the United States for Sarconeos in Duchenne Muscular Dystrophy (DMD)
Mar 28, 2018 08:00AM BIOPHYTIS: 2017 Full Year Results
Mar 20, 2018 03:36PM BIOPHYTIS files for Orphan Drug Designation for Sarconeos in Duchenne Muscular Dystrophy (DMD)
Mar 1, 2018 02:00AM BIOPHYTIS updates on SARA clinical study of Sarconeos in sarcopenia and presents four posters at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Miami
Dec 19, 2017 01:45AM BIOPHYTIS to Participate in Corporate Access Event in San Francisco, January 8 - 10, 2018
Dec 4, 2017 01:45AM Biophytis has FAMHP Approval to conduct SARA-INT phase 2b Interventional Study of Sarconeos in Sarcopenia in Belgium
Nov 1, 2017 02:45AM BIOPHYTIS Completes a €7.5 M Capital Increase to Help Accelerate Pipeline Programs in Orphan Pediatric Diseases
Oct 30, 2017 01:45AM BIOPHYTIS Has FDA Approval to Initiate SARA-INT Phase 2b Interventional Study of Sarconeos in Sarcopenia
Oct 27, 2017 01:45AM Biophytis Appoints Professor Thomas Voit to Scientific Advisory Board to Help Accelerate Pipeline Programs in Orphan Pediatric Diseases
Oct 26, 2017 12:00PM BIOPHYTIS: Half-Year Financial Report as of June 30, 2017
Oct 11, 2017 06:29AM BIOPHYTIS completes a €10.4 M capital increase to finance mid-stage clinical trials for two novel anti-aging drug-candidates
Sep 25, 2017 08:00AM BIOPHYTIS filed IND application for approval by FDA of SARA-INT Phase 2b study of Sarconeos in Sarcopenia
Sep 8, 2017 08:00AM Biophytis Clinical Stage Drug-Candidate Sarconeos Demonstrates Efficacy in Preclinical Models of Duchenne Muscular Dystrophy
Jun 16, 2017 12:03PM BIOPHYTIS selects SGS Life Science Services to conduct MACA-PK, clinical study of Macuneos in dry AMD
May 11, 2017 08:00AM BIOPHYTIS: First patient-in in the United States and opening of 2 clinical centers for the SARA-OBS study on Sarcopenia
Apr 27, 2017 12:08PM BIOPHYTIS: 2016 Full Year Results
Apr 4, 2017 07:00AM BIOPHYTIS secures funding for phase 2B clinical trial in Sarcopenia, SARA-INT
Mar 27, 2017 08:00AM BIOPHYTIS opens the first clinical centers in Europe and starts the recruitment of sarcopenic patients for SARA-OBS study